Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts1
Department of Neurological Surgery, Brain Tumor Research Center (Y.Y., M.T.K., T.K., K.S.B.), and Division of Hematology-Oncology (C.O.N., J.W.P.), University of California, San Francisco, San Francisco, CA 94103; and Hermes Biosciences, Inc., South San Francisco, CA 94080 (D.C.D., J.W.P.); USA
3 Address correspondence to Krystof S. Bankiewicz, Department of neurological Surgery, University of California, San Francisco, 1855 Folsom Street, Mission Center Building room 226, San Francisco, CA 94103, USA (Krystof.Bankiewicz{at}ucsf.edu).
 |
Abstract |
|---|
Despite multimodal treatment options, the response and survival rates for patients with malignant gliomas remain dismal. Clinical trials with convection-enhanced delivery (CED) have recently opened a new window in neuro-oncology to the direct delivery of chemotherapeutics to the CNS, circumventing the blood-brain barrier and reducing systemic side effects. Our previous CED studies with liposomal chemotherapeutics have shown promising antitumor activity in rodent brain tumor models. In this study, we evaluated a combination of nanoliposomal topotecan (nLs-TPT) and pegylated liposomal doxorubicin (PLD) to enhance efficacy in our brain tumor models, and to establish a CED treatment capable of improving survival from malignant brain tumors. Both liposomal drugs decreased key enzymes involved in tumor cell replication in vitro. Synergistic effects of nLs-TPT and PLD on U87MG cell death were found. The combination displayed excellent efficacy in a CED-based survival study 10 days after tumor cell implantation. Animals in the control group and those in singleagent groups had a median survival of less than 30 days, whereas the combination group experienced a median survival of more than 90 days. We conclude that CED of two liposomal chemotherapeutics (nLs-TPT and PLD) may be an effective treatment option for malignant gliomas.
Keywords: brain tumor, CED, convection-enhanced delivery, glioma, liposome, topotecan
Received January 27, 2006; Accepted May 30, 2006
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. G. Hodgson, R.-F. Yeh, A. Ray, N. J. Wang, I. Smirnov, M. Yu, S. Hariono, J. Silber, H. S. Feiler, J. W. Gray, et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts Neuro Oncology, October 1, 2009; 11(5): 477 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Inoue, Y. Yamashita, M. Nishihara, S. Sugiyama, Y. Sonoda, T. Kumabe, M. Yokoyama, and T. Tominaga Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models Neuro Oncology, April 1, 2009; 11(2): 151 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Krauze, C. O. Noble, T. Kawaguchi, D. Drummond, D. B. Kirpotin, Y. Yamashita, E. Kullberg, J. Forsayeth, J. W. Park, and K. S. Bankiewicz Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts Neuro Oncology, October 1, 2007; 9(4): 393 - 403. [Abstract] [Full Text] [PDF]
|
|